One of the fundamental challenges in cancer treatment is cancer resistance and relapse. A reason for this acquired resistance may be the presence of small minority of cells in the tumor called cancer stem cells (CSC). Most current anti-cancer chemotherapeutics primarily target either differentiated or proliferating cancer cells, and concretively, will not be effective against CSCs.
With more than 780,000 new cases diagnosed every year, liver cancer is the fifth most common cancer worldwide. Almost 400,000 new cases are diagnosed annually in China, Japan and South Korea, 52,000 in the EU and about 30,000 in the United States. Men are significantly more affected overall than women.
Liver cancer causes death more often than many other tumors, and patients are usually diagnosed with late-stage disease.
Bringing a new hope to cancer patients by providing innovative approaches for a better care
Philippe Halfon, CEO of Genoscience Pharma
